|
| Study | Marker | Type of cancer | Threshold | Assessment period | Results |
|
| Parker et al. [22] | Albumin | Ovarian cancer | 3.5 & 4.1 g/dL | Before operation | Low-albumin level (continuous value) was associated with worse OS |
|
| Lis et al. [19] | Albumin | Breast cancer | 3.5 g/dL | Before operation | Low-albumin level (<3.5 g/dL) was related to higher death rate |
|
| Lai et al. [7] | Albumin | Colon cancer | 3.5 g/dL | Before operation | Hypoalbuminemia (<3.5 g/dL) was associated with increased morbidity and mortality |
|
| Seebacher et al. [67] | Albumin | Endometrial cancer | 4.21 g/dL or continuous | Before operation | Increased albumin level (continuous) was related to better DFS and PFS |
|
| Hashimoto et al. [14] | CRP | HCC | 1.0 mg/dL | Before operation | Elevated CRP (>1) was significant predictor of worse OS and RFS |
|
| Lehrer et al. [28] | CRP | Prostate cancer | NA (continuous) | Before radiation | There was a significant correlation of CRP level with PSA |
|
| Crumley et al. [16] | CRP | Gastroesophageal cancer | 1.0 mg/dL | Before operation | Elevated CRP (>1) was independent predictor of CSS |
|
| Jones et al. [4] | CRP | Lung cancer | 0.4 mg/dL | Before operation | Elevated CRP (>0.4) was related to larger tumor size, advanced tumor stage, and incomplete resection |
|
| Karakiewicz et al. [32] | CRP | RCC | 0.4 & 2.3 mg/dL | Before nephrectomy | Elevated CRP (>2.3) was an informative predictor of worse CSS |
|
| Beer et al. [29] | CRP | Metastatic prostate cancer | 0.8 mg/dL | Before docetaxel based chemotherapy | Elevated CRP (>0.8) was a strong predictor of poor OS and lower PSA response to chemotherapy |
|
| Hefler et al. [23] | CRP | Ovarian cancer | 1.0 mg/dL | Before surgery | Elevated CRP (>1.0 & continuous) was associated with postoperative residual tumor and worse OS |
|
| Shiu et al. [8] | CRP | Colorectal cancer | 0.5 mg/dL | Before surgery | Elevated CRP (>0.5) was correlated with larger tumor size, higher stage, and poorer CSS |
|
| Crumley et al. [17] | GPS | Inoperable gastroesophageal cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before nonsurgical treatment | High GPS was significant predictor of worse CSS |
|
|
Al Murri et al. [20] | GPS | Metastatic breast cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before non-surgical treatment | High GPS was significant predictor of worse CSS |
|
| Ramsey et al. [33] | GPS | Metastatic RCC | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before treatment | High GPS was significant predictor of worse CSS |
|
| Polterauer et al. [25] | GPS | Cervical cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before surgery | High GPS was significant predictor of worse OS and DFS |
|
| Vashist et al. [18] | GPS | Esophageal cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before surgery | High GPS was a strong prognosticator of perioperative morbidity and worse DFS and OS |
|
| Kinoshita et al. [15] | GPS | HCC | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before treatment | High GPS was independently associated with worse CSS |
|
| Leitch et al. [9] | mGPS | Colorectal cancer (operable or unresectable) | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before treatment | High mGPS was independently associated with worse CSS in patients with either operable or unresectable colorectal cancer |
|
| Jiang et al. [13] | mGPS | Gastric cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before surgery | High mGPS was independently associated with worse OS irrespective of cancer stage |
|
| Ishizuka et al. [10] | mGPS | Unresectable colorectal cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before chemotherapy | High mGPS (1/2) was an independent risk factor of poor CSS |
|
| La Torre et al. [27] | mGPS | Pancreatic cancer | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before surgery | High mGPS was independently associated with worse OS irrespective of cancer stage |
|
| Lamb et al. [34] | mGPS | RCC | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | Before surgery | High mGPS was significantly independent predictors of worse OS and CSS |
|
| Cho et al. [24] | NLR | Ovarian cancer | 2.6 | Before surgery | Positive NLR (>2.6) showed worse OS and DFS than negative NLR (<2.6) |
|
| Chua et al. [11] | NLR | Metastatic colorectal cancer | 5 | Before chemotherapy | Elevated NLR (>5) was independently associated with less clinical response to chemotherapy and worse OS and PFS |
|
| Azab et al. [21] | NLR | Breast cancer | Multiple cut-offs
(1.8, 2, 45, 3, 33) | Before chemotherapy | High NLR (>3.3) was an independent significant predictor of all-cause mortality |
|
| Keizman et al. [70] | NLR | Metastatic CRPC | 3 | Before ketoconazole | Low NLR (≤3.0) was significantly associated with better PFS |
|
| Keizman et al. [71] | NLR | Metastatic RCC | 3 | Before sunitinib | Low NLR (≤3.0) was independent predictor of better response to sunitinib and favorable PFS and OS |
|
| Lee et al. [26] | NLR | Cervical cancer | 1.9 | Before treatment | High NLR (≥1.9) was related to more advanced stage and increased NLR (continuous) was an independent predictor of worse PFS and OS |
|
| Yao et al. [5] | NLR | Advanced lung cancer | 2.63 | Before chemotherapy | Low NLR (≤2.63) was independently associated with better clinical response to chemotherapy and favorable OS and PFS |
|
